share_log

Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company

Edwards Lifesciences Corporation (NYSE:EW) Is Largely Controlled by Institutional Shareholders Who Own 85% of the Company

愛德華生命科學公司(紐交所代碼:EW)主要由持有公司85%股份的機構股東控制。
Simply Wall St ·  2024/12/23 19:47

Key Insights

關鍵洞察

  • Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable to their trading decisions
  • A total of 22 investors have a majority stake in the company with 51% ownership
  • Recent sales by insiders
  • 鑑於機構在股票中的大額股份,愛德華生命科學的股價可能會受到他們交易決策的影響。
  • 共有22位投資者在該公司擁有多數股份,持股51%。
  • 高管近期的賣出行爲

Every investor in Edwards Lifesciences Corporation (NYSE:EW) should be aware of the most powerful shareholder groups. With 85% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

每位在愛德華生命科學公司(紐交所:EW)投資的股東都應該意識到最強大的股東群體。機構以85%的股份持有公司最多的股票。換句話說,該群體從對公司的投資中獲得的收益(或損失)最大。

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

由於機構擁有大量資金和研究能力,機構持股在個別投資者中往往具有很大的影響力。因此,投資者在一家公司擁有相當數量的機構資金通常被視爲一個可取的特徵。

Let's delve deeper into each type of owner of Edwards Lifesciences, beginning with the chart below.

讓我們深入探討愛德華生命科學每種所有者的類型,從下面的圖表開始。

big
NYSE:EW Ownership Breakdown December 23rd 2024
紐交所:EW 股權結構 2024年12月23日

What Does The Institutional Ownership Tell Us About Edwards Lifesciences?

機構持股情況告訴我們關於Edwards Lifesciences的什麼信息?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與一個常見的指數回報進行比較。因此,他們通常會考慮購買納入相關基準指數的大型公司股票。

As you can see, institutional investors have a fair amount of stake in Edwards Lifesciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Edwards Lifesciences, (below). Of course, keep in mind that there are other factors to consider, too.

正如您所見,機構投資者在愛德華生命科學中持有相當數量的股份。這意味着爲這些機構工作的分析師對該股票進行了研究,並且他們喜歡它。但是,就像其他任何人一樣,他們也可能是錯的。如果兩個大型機構投資者同時試圖賣出一隻股票,股價大幅下跌並不罕見。因此,查看愛德華生命科學過去的收益軌跡是值得的(見下文)。當然,記住還有其他因素需要考慮。

big
NYSE:EW Earnings and Revenue Growth December 23rd 2024
紐交所:EW 盈利和營業收入增長 2024年12月23日

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Edwards Lifesciences. Looking at our data, we can see that the largest shareholder is The Vanguard Group, Inc. with 11% of shares outstanding. For context, the second largest shareholder holds about 9.3% of the shares outstanding, followed by an ownership of 5.3% by the third-largest shareholder.

投資者應注意,機構實際上擁有公司超過一半的股份,因此他們可以集體發揮顯著的影響力。對沖基金在愛德華生命科學的股份並不多。根據我們的數據,最大的股東是先鋒集團,持有11%的流通股份。作爲背景,第二大股東持有約9.3%的流通股份,第三大股東則持有5.3%的股份。

After doing some more digging, we found that the top 22 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

經過進一步挖掘,我們發現前22名股東共計擁有公司51%的股份,這表明沒有單一股東對公司擁有顯著的控制權。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然研究一家公司的機構持股數據是有意義的,但研究分析師的情緒以了解市場趨勢同樣也是有意義的。現在有相當多的分析師關注這隻股票,因此了解他們對未來的整體看法可能會很有用。

Insider Ownership Of Edwards Lifesciences

Edwards Lifesciences的內部所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

雖然對內幕人的確切定義可能是主觀的,但幾乎所有人都認爲董事會成員是內幕人。公司管理層向董事會負責,後者應該代表股東的利益。值得注意的是,有時候高層管理者自己也是董事會成員。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人擁有股份是一件好事。然而,在某些情況下,這使得其他股東更難讓董事會對決策負責。

Our most recent data indicates that insiders own less than 1% of Edwards Lifesciences Corporation. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$399m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

我們最新的數據表明,內部人士擁有愛德華生命科學公司不到1%的股份。由於它是一家大公司,我們只期待內部人士持有小部分股份。但值得注意的是,他們擁有價值39900萬美元的股份。看到至少一些內部人士的持股總是好的,但可能值得檢查這些內部人士是否在出售。

General Public Ownership

公衆持股

The general public, who are usually individual investors, hold a 14% stake in Edwards Lifesciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公衆,通常是個人投資者,持有愛德華生命科學14%的股份。雖然這部分持股相當可觀,但如果該決策與其他大型股東不同,這可能不足以改變公司政策。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Edwards Lifesciences better, we need to consider many other factors.

始終值得考慮不同的群體誰擁有公司的股票。但要更好地了解愛德華生命科學,我們需要考慮許多其他因素。

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.

我喜歡深入了解一家公司過去的表現。您可以免費訪問這張互動圖表,查看過去的盈利、營業收入和現金流。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能想考慮這家公司是會增長還是縮小。幸運的是,你可以查看這份免費的報告,了解分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是根據過去十二個月的數據計算得出的,指的是截至財務報表日期的月份最後一天的12個月期間。這可能與完整年度的年報數字不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論